Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.70 |
| ▸ | NPC1 | O15118 | 7/20 | 0.70 |
| ▸ | RAB9A | P51151 | 7/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.70 |
| ▸ | HPGD | P15428 | 4/20 | 0.70 |
| ▸ | POLB | P06746 | 3/20 | 0.70 |
| ▸ | CASP3 | P42574 | 2/20 | 0.70 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.70 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.70 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | ESR1 | P03372 | 2/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.59 |
| ▸ | GFER | P55789 | 1/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7905531 | 1.00 | SMN1; SMN2 (0.70) | SMN1; SMN2NPC1RAB9AKDM4EHPGD | |
| SCHEMBL13528498 | 0.98 | NPC1 (0.72) | SMN1; SMN2NPC1RAB9AKDM4EHPGD | |
| SCHEMBL19846132 | 0.96 | SMN1; SMN2 (0.66) | SMN1; SMN2NPC1RAB9AKDM4EHPGD | |
| SCHEMBL19846131 | 0.96 | SMN1; SMN2 (0.66) | SMN1; SMN2NPC1RAB9AKDM4EHPGD | |
| SCHEMBL13067483 | 0.93 | NPC1 (0.62) | SMN1; SMN2NPC1RAB9AKDM4EHPGD | |
| SCHEMBL10045323 | 0.93 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9AKDM4EHPGD | |
| SCHEMBL5371887 | 0.92 | NPC1 (0.73) | SMN1; SMN2NPC1RAB9AKDM4EHPGD | |
| SCHEMBL2243994 | 0.92 | SMN1; SMN2 (0.79) | SMN1; SMN2NPC1RAB9AKDM4EHPGD | |
| SCHEMBL2242798 | 0.92 | SMN1; SMN2 (0.79) | SMN1; SMN2NPC1RAB9AKDM4EHPGD | |
| SCHEMBL712315 | 0.91 | SMN1; SMN2 (0.59) | SMN1; SMN2NPC1RAB9AKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106981661-A | Preparation method of lithium ion battery electrode material | 南京工业大学 | 2017-07-25 | — | — | CN | claimed |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | SUMMIT (OXFORD) LIMITED (GB) | 2011-08-11 | — | — | US | claimed |
| CN-106794264-B | Conjugates comprising neurotensin receptor ligands and uses thereof | 3B制药有限公司 | 2021-03-23 | — | — | CN | disclosed |
| CN-106981661-B | Preparation method of lithium ion battery electrode material | 南京工业大学 | 2019-08-23 | — | — | CN | disclosed |
| EP-3251694-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit (Oxford) Limited (GB) | 2017-12-06 | — | — | EP | disclosed |
| CN-107056723-A | It is a kind of that there is the compound for suppressing vascular endothelial growth factor receptor signal transduction | 云南大学 | 2017-08-18 | — | — | CN | disclosed |
| CN-106981661-A | Preparation method of lithium ion battery electrode material | 南京工业大学 | 2017-07-25 | — | — | CN | disclosed |
| CN-106794264-A | Conjugates comprising neurotensin receptor ligands and uses thereof | 3B制药有限公司 | 2017-05-31 | — | — | CN | disclosed |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-16 | — | — | US | disclosed |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-09 | — | — | US | disclosed |
| US-8518980-B2 | Treatment of Duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-27 | — | — | US | disclosed |
| US-8501713-B2 | Drug combinations for the treatment of duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-06 | — | — | US | disclosed |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | SUMMIT (OXFORD) LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| EP-2170396-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | BioMarin IGA Limited (BS) | 2010-04-07 | — | — | EP | disclosed |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT (OXFORD) LIMITED (GB) | 2009-03-19 | — | — | US | disclosed |
| WO-2009019504-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2009-02-12 | — | — | WO | disclosed |
| EP-1986633-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit Corporation Plc (GB) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007091106-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | PYGM, CPT1B, GYS1 | SMN1; SMN2 4/4885NPC1 2477/4885RAB9A 3748/4885 |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | PYGM, CPT1B, GYS1 | SMN1; SMN2 4/4885NPC1 2477/4885RAB9A 3748/4885 |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | SMN1; SMN2 9/4885NPC1 3637/4885RAB9A 4325/4885 |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | SMN1; SMN2 9/4885NPC1 3637/4885RAB9A 4325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.